Odile Rundquist
Directeur/Membre du Conseil chez Amazentis SA
Profil
Odile Rundquist is currently a Director at Amazentis SA and Vandria SA. Previously, she worked as a Research Analyst at Baader Helvea AG from 2009 to 2014 and as an Analyste at Bank Vontobel AG (Research Firm).
Postes actifs de Odile Rundquist
| Sociétés | Poste | Début |
|---|---|---|
Amazentis SA
 Amazentis SA Miscellaneous Commercial ServicesCommercial Services Amazentis SA is a Swiss innovative life science company that focuses on developing products targeting mitochondrial health for advanced nutrition. The company was founded in 2007 by Pierre Landolt, Patrick Aebischer, and Chris Rinsch, and it is currently based in Lausanne, Switzerland. The company has published its research on Mitopure™ Urolithin A in top peer-reviewed scientific journals, including Nature Medicine, Nature Metabolism, JAMA Network Open, and European Journal of Clinical Nutrition. Amazentis has a strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™. Brian Ray has been the CEO of the company since 2023. | Directeur/Membre du Conseil | 01/12/2017 |
Vandria SA
 Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Directeur/Membre du Conseil | - |
Anciens postes connus de Odile Rundquist
| Sociétés | Poste | Fin |
|---|---|---|
Baader Helvea AG
 Baader Helvea AG Investment Banks/BrokersFinance Baader Helvea AG (Baader Helvea) s the research-based Swiss brokerage subsidiary of Baader Bank AG (XE: BWB) in Germany. Formerly known as Helvea SA, established in 1990, the firm is located in Geneva and specializes in equity research, sales, sales trading, execution and administration, and services institutional clients worldwide, including pension funds, insurance funds, unit trusts, balanced funds and hedge funds. Their core market is Switzerland with a focus on small- and mid-cap companies; however, they also have expertise in European equity especially in those sectors in which Swiss companies operate as global players, such as banking, insurance, healthcare, food manufacturing, chemicals and luxury goods. The firm's research process focuses on company analysis and includes a company visitation program. They aim to identify companies likely to generate superior returns for shareholders and to evaluate sector or company-specific trends. | Analyst-Equity | - |
| Bank Vontobel AG (Research Firm) | Analyst-Equity | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Baader Helvea AG
Baader Helvea AG Investment Banks/BrokersFinance Baader Helvea AG (Baader Helvea) s the research-based Swiss brokerage subsidiary of Baader Bank AG (XE: BWB) in Germany. Formerly known as Helvea SA, established in 1990, the firm is located in Geneva and specializes in equity research, sales, sales trading, execution and administration, and services institutional clients worldwide, including pension funds, insurance funds, unit trusts, balanced funds and hedge funds. Their core market is Switzerland with a focus on small- and mid-cap companies; however, they also have expertise in European equity especially in those sectors in which Swiss companies operate as global players, such as banking, insurance, healthcare, food manufacturing, chemicals and luxury goods. The firm's research process focuses on company analysis and includes a company visitation program. They aim to identify companies likely to generate superior returns for shareholders and to evaluate sector or company-specific trends. | Finance |
| Bank Vontobel AG (Research Firm) | Finance |
Amazentis SA
Amazentis SA Miscellaneous Commercial ServicesCommercial Services Amazentis SA is a Swiss innovative life science company that focuses on developing products targeting mitochondrial health for advanced nutrition. The company was founded in 2007 by Pierre Landolt, Patrick Aebischer, and Chris Rinsch, and it is currently based in Lausanne, Switzerland. The company has published its research on Mitopure™ Urolithin A in top peer-reviewed scientific journals, including Nature Medicine, Nature Metabolism, JAMA Network Open, and European Journal of Clinical Nutrition. Amazentis has a strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™. Brian Ray has been the CEO of the company since 2023. | Commercial Services |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Health Technology |
